Breaking News Instant updates and real-time market news.

SWKS

Skyworks

$67.98

1.05 (1.57%)

, QRVO

Qorvo

$61.18

0.55 (0.91%)

09:23
01/03/19
01/03
09:23
01/03/19
09:23

Skyworks, Qorvo among semi names with most Apple exposure, says Morgan Stanley

Morgan Stanley analyst Craig Hettenbach maintains his Cautious view on the Semiconductors sector, telling investors that the sizeable iPhone miss in China and a weaker China PMI reading this week provide further evidence of a strong downward bias in "the most important growth region for semis." He sees more reasons for investors to reduce exposure to semis, rather than add, ahead of what he expects to be a challenging earnings season, Hettenbach noted. In terms of exposure to Apple (AAPL), he estimates Skyworks (SWKS) has 45% exposure, followed by Qorvo (QRVO) at about 35% and Broadcom (AVGO) at 15%- 20%. Beyond the companies with the greatest Apple exposure, Hettenbach also highlight risks to broad-based suppliers such as Texas Instruments (TXN), Amphenol (APH), ON Semiconductor (ON), NXP Semiconductors (NXPI), Analog Devices (ADI) and Cypress Semiconductor (CY), calling out ON as his top Underweight idea.

SWKS

Skyworks

$67.98

1.05 (1.57%)

QRVO

Qorvo

$61.18

0.55 (0.91%)

AVGO

Broadcom

$253.45

-0.57 (-0.22%)

AAPL

Apple

$157.94

0.09 (0.06%)

TXN

Texas Instruments

$94.46

0.06 (0.06%)

APH

Amphenol

$79.86

-0.75 (-0.93%)

ON

ON Semiconductor

$16.79

0.28 (1.70%)

NXPI

NXP Semiconductors

$75.02

1.82 (2.49%)

ADI

Analog Devices

$85.90

0.06 (0.07%)

CY

Cypress Semiconductor

$12.85

0.14 (1.10%)

  • 07

    Jan

  • 07

    Jan

  • 07

    Jan

  • 08

    Jan

  • 08

    Jan

  • 08

    Jan

  • 25

    Feb

  • 08

    Mar

SWKS Skyworks
$67.98

1.05 (1.57%)

01/03/19
NEED
01/03/19
NO CHANGE
Target $77
NEED
Buy
Skyworks price target lowered to $77 from $99 at Needham
Needham analyst N. Quinn Bolton lowered his price target on Skyworks (SWKS) to $77 after the negative Q1 revenue pre-announcement from Apple (AAPL). The analyst believes that the company will be able to achieve its previously guided metrics in the quarter but will then be faced with an inventory correction in Q2 and Q3 amid lower iPhone unit sell-throughs. Bolton keeps his Buy rating on Skyworks longer term and sees his implied 10-times forward earnings valuation multiple as conservative.
12/10/18
12/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. FedEx (FDX) downgraded to Neutral from Buy at BofA/Merrill with analyst Ken Hoexter citing the board's surprise move to change its Express CEO. 2. Unilever downgraded to Underweight from Neutral at JPMorgan with analyst Celine Pannuti saying she views consensus expectations as elevated. 3. Regions Financial (RF) and KeyCorp (KEY) were downgraded to Reduce from Neutral at Nomura Instinet. 4. Qorvo (QRVO) and Skyworks (SWKS) were downgraded to Sector Weight from Overweight at KeyBanc. 5. Navistar (NAV) and Oshkosh (OSK) were downgraded to Sell from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/10/18
KEYB
12/10/18
DOWNGRADE
KEYB
Sector Weight
Skyworks downgraded to Sector Weight at KeyBanc on weakening smartphone demand
As previously reported, KeyBanc analyst Weston Twigg downgraded Skyworks (SWKS) to Sector Weight from Overweight given further weakening Apple (AAPL) iPhone demand trends, weaker than expected China smartphone demand, indications Qualcomm (QCOM) is finally gaining market share on RF360 amid transition to 5G in 2H19, and modest share lost in China smartphones to Qorvo (QRVO) this year as a result of RF Fusion phase 6 and signs of supply constraints at Skyworks. While the analyst believes Skyworks remains well positioned for 5G longer term and sees modest downside risk with the stock trading near trough valuation, Twigg struggles to see positive catalysts given the disappointing iPhone cycle and weakening demand environment for China smartphones.
12/10/18
KEYB
12/10/18
DOWNGRADE
KEYB
Sector Weight
Skyworks downgraded to Sector Weight from Overweight at KeyBanc
QRVO Qorvo
$61.18

0.55 (0.91%)

12/12/18
JPMS
12/12/18
NO CHANGE
Target $98
JPMS
Overweight
Qorvo risk/reward favorable for patient investors, says JPMorgan
After hosting meetings with management, JPMorgan analyst Bill Peterson believes Qorvo is executing well "on what it can control in a weak smartphone unit demand environment." The company continues expanding its design win pipeline and driving content growth on late stage 4G and 5G adoption in mobile, Peterson tells investors in a research note. Further, he believes 5G also represents a "strong growth opportunity" for Qorvo in non-mobile. The analyst thinks the compamy is well positioned to drive dollar content higher across smartphone vendors next year. He sees the stock outperforming over the next 12-18 months and keeps an Overweight rating on the name with a $98 price target. Qorvo shares offer a "favorable risk/reward profile for patient investors from here," says Peterson.
12/18/18
CHLM
12/18/18
INITIATION
Target $8
CHLM
Buy
Akoustis initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Anthony Stoss started Akoustis (AKTS) with a Buy rating and $8 price target. The analyst notes that the company sits in a "unique position" with BAW filters designed with a proprietary single crystal structure. Its filters offer superior performance at higher frequencies than the two dominant players - Broadcom (AVGO) and Qorvo (QRVO) - as they can handle higher power, have better acoustic performance, transfer heat out much faster, and are 23-times smaller. Stoss believes these characteristics will allow Akoustis to penetrate three enormous markets in a meaningful way.
01/03/19
NEED
01/03/19
NO CHANGE
Target $66
NEED
Buy
Qorvo price target lowered to $66 from $78 at Needham
Needham analyst N. Quinn Bolton lowered his price target on Qorvo (QRVO) to $66 after the negative Q1 revenue pre-announcement from Apple (AAPL). The analyst believes that the company will be able to achieve its previously guided metrics in the quarter but will then be faced with an inventory correction in Q2 and Q3 amid lower iPhone unit sell-throughs. Bolton also keeps his Buy rating on Qorvo longer term and sees his implied 10-times forward earnings valuation multiple as conservative.
AVGO Broadcom
$253.45

-0.57 (-0.22%)

12/07/18
CHLM
12/07/18
NO CHANGE
Target $305
CHLM
Buy
Broadcom price target raised to $305 from $300 at Craig-Hallum
Craig-Hallum analyst Anthony Stoss maintained a Buy rating on Broadcom (AVGO) and raised his price target to $305 following the company's above-estimates results on a better than expected wireless business due to strong legacy iPhone sales. Stoss tells investors in a research note that he believes Broadcom will likely raise its dividend 30%+ in 2019 as it cuts CA spending to $900M, driving significant free cash flow. The analyst looks for Broadcom's wireless business to return to growth in FY20 as it wins back the lost socket at Apple (AAPL) and as 5G will drive strong demand for its BAW filters.
12/21/18
JPMS
12/21/18
NO CHANGE
Target $325
JPMS
Overweight
JPMorgan adds Broadcom to Analyst Focus List, names a top pick for 2019
JPMorgan analyst Harlan Sur names Broadcom his top pick in semiconductors heading into 2019. The analyst also added the shares to his firm's Analyst Focus List while maintaining an Overweight rating on the name with a $325 price target. Sur sees "multiple growth tailwinds" for Broadcom, including the cloud datacenter networking upgrade cycle and iPhone content gains. Further, he believes the company has a "strong and diversified tech infrastructure business model, solid free cash flow generation, and another strong dividend raise coming next year."
12/07/18
MLTK
12/07/18
UPGRADE
MLTK
Buy
Broadcom upgraded to Buy from Hold at Miller Tabak
AAPL Apple
$157.94

0.09 (0.06%)

01/03/19
BERN
01/03/19
NO CHANGE
BERN
Apple iPhone fall-off worse than most expected, says Bernstein
Bernstein analyst A.M. Sacconaghi says that while no one is likely to be surprised by Apple's December quarter miss, the magnitude of the fall-off in iPhones is likely worse than most expected. The analyst notes that Apple squarely attributed its shortfall to China but iPhone revenues outside of China still appeared to fall $3B-plus short of Apple's expectations. While a meaningful portion of the China weakness is macro driven, Apple appears to have lost material share in China in Q4 despite its new product launch, Sacconaghi contends.
01/03/19
DADA
01/03/19
NO CHANGE
Target $260
DADA
Buy
Apple price target lowered to $260 from $280 at DA Davidson
DA Davidson analyst Tom Forte lowered his price target on Apple to $260 after its "rare" pre-announcement that highlighted the company's "tightrope" in traversing its China exposure with 20% of sales from the country amid the "prolonged and escalating" trade war. The analyst notes that while the iPhone sales for December quarter look to be disappointing, he was encouraged by the performance of other products and services in the quarter, keeping his Buy rating on the shares. Forte also believes that Apple may boost its stock buyback since it typically updates its capital program in April/May, given its $130B net cash balance and repeated intention to become net-cash neutral in the future.
01/03/19
KEYB
01/03/19
NO CHANGE
KEYB
Sector Weight
Apple guidance revision suggests more issues than just China, says KeyBanc
KeyBanc analyst Andy Hargreaves notes Apple preannounced much weaker Q1 results than he anticipated. While the company mostly blamed China and macroeconomic factors, the analyst believes pricing power problems in iPhone and peaking App Store monetization contributed significantly to the weakness in the quarter. While Apple's valuation is certainly more attractive at about 7 times EV/EBITDA, Hargreaves believes the company still faces significant risks around iPhone pricing and App Store monetization. He reiterates a Sector Weight rating on the shares.
01/03/19
NEED
01/03/19
NO CHANGE
Target $180
NEED
Buy
Apple price target lowered to $180 from $200 at Needham
Needham analyst Laura Martin lowered her price target on Apple to $180 after its Q1 pre-announcement on softer iPhone revenues. However, the analyst also keeps her Buy rating on the shares and believes that the company represents "one of the cheapest ways to participate in the global shift toward mobile device". Martin is also positive on yesterday's disclosure that Apple's Services revenue hit record highs in every geographic segment, wearable revenues rose nearly 50%, device ecosystem has grown by 100M units, and that the company hit "all-time record revenue in several first world countries."
TXN Texas Instruments
$94.46

0.06 (0.06%)

12/03/18
UBSW
12/03/18
NO CHANGE
UBSW
Meaningful reset in Street semiconductor growth expectations coming, says UBS
UBS analyst Timothy Arcuri believes Street growth expectations for semiconductors are too high and thinks there could be a meaningful reset in expectations coming over the next couple of months. He cites the October SIA data, which showed a decline of revenues on broad-based weakness across memory and analog MCU. Publicly traded companies in the semiconductors space include AMD (AMD), Intel (INTC), Marvell (MRVL), Microchip (MCHP), Micron (MU), Nvidia (NVDA), Qualcomm (QCOM) and Texas Instruments (TXN).
11/07/18
BNCH
11/07/18
NO CHANGE
Target $45
BNCH
Buy
Diodes results, guidance 'much better' than feared, says Benchmark
Benchmark analyst Gary Mobley reiterated his Buy rating on Diodes (DIOD) shares after the company's Q3 results and Q4 guidance were both "much better" than feared at a time when peers such as Texas Instruments (TXN) are "struggling." He maintains a $45 price target on Diodes, stating that he believes the company can take market share in 2018.
11/05/18
SBSH
11/05/18
NO CHANGE
SBSH
Citi recommends buying Semis that have lowered guidance
Semiconductors are in the "bottom-forming" process as estimates are declining in line with previous corrections and most of the downside to estimates should be out by January barring a recession, Citi analyst Christopher Danely tells investors in a research note. The analyst recommends building positions in companies that have lowered guidance such as Buy-rated Texas Instruments (TXN), which is his top pick. He also has Buy ratings on Microchip (MCHP) and ON Semiconductor (ON). Danely's lone Sell rated name is AMD (AMD).
10/24/18
LOOP
10/24/18
NO CHANGE
Target $90
LOOP
Hold
Silicon Labs price target lowered to $90 from $110 at Loop Capital
Loop Capital analyst Cody Acree lowered his price target for Silicon Labs to $90 from $110, while reiterating a Hold rating on the shares. Given the company's size, at just under a $1B run-rate, the analyst believes Silicon Labs has many company specific drivers in IoT, Infrastructure and Automotive that should help insulate it to a degree from the broad macro semi demand slowdown being seen by Texas Instruments (TXN) and likely many other chip companies. However, Acree does not expect Silicon Labs' specific drivers to fully offset the macro caution in OEM build rates and the likelihood that OEMs and distributors will be working to maintain very lean inventories, particularly given that chip industry delivery lead times remain at low levels.
APH Amphenol
$79.86

-0.75 (-0.93%)

10/09/18
GSCO
10/09/18
UPGRADE
Target $108
GSCO
Buy
Amphenol upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Mark Delaney upgraded Amphenol to Buy and raised his price target for the shares to $108 from $95. The company's "best in class" execution and "diverse" end markets position it well in a tougher cyclical environment, Delaney tells investors in a research note.
10/16/18
MSCO
10/16/18
NO CHANGE
MSCO
Semi fundamentals look worse today than in 2015 down cycle, says Morgan Stanley
Morgan Stanley analyst Craig Hettenbach noted that the selloff in semiconductor stocks has been "swift and painful" and could be getting overdone near-term, though he worries the group is "by no means out of the woods" given his view that semi fundamentals today are worse than they were in the 2015 down cycle. Specifically, Hettenbach points to the degree of excess that built up in the supply chain this time, stating that the increase in lead times, double ordering, and inventory accumulation is markedly different to the period that preceded the last time there were broad-based semi estimate cuts in the second half of 2015. Semi sector estimates have only just recently started to come down and there are growing investor expectations that companies will guide Q4 revenue at least a few percent below the Street, added Hettenbach, who said the "upcoming earnings season will be the big test."
10/03/18
MSCO
10/03/18
NO CHANGE
MSCO
Morgan Stanley cuts semiconductor estimates ahead of earnings season
Morgan Stanley analysts Craig Hettenbach, Joseph Moore and Vinayak Rao cut their estimates for Q4 and 2019 for several seminconductor makers to reflect what they see as the start of an inventory correction that is likely to be most pronounced in autos and industrial applications. Sentiment in the semiconductor group has quickly turned negative, which could lead to trading bounces in stocks, but if estimates start to come down as they expect, it will be difficult for stocks "to work," the analysts tells investors. The analysts lowered their price targets on Amphenol (APH) to $100 from $102, on Analog Devices (ADI) to $108 from $110, on TE Connectivity (TEL) to $102 from $107, on Microchip (MCHP) to $95 from $98, on Maxim Integrated to $59 from $60, on Qorvo (QRVO) to $72 from $75 and on Skyworks (SWKS) to $79 from $80.
10/09/18
10/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Walmart (WMT) upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying the retailer is reaping returns on the many years of investment in e-commerce and customer service. 2. Cree (CREE) upgraded to Neutral from Underweight at JPMorgan with analyst Paul Coster saying he sees a more balanced risk/reward following the recent underperformance of the shares. 3. Amphenol (APH) upgraded to Buy from Neutral at Goldman Sachs with analyst Mark Delaney saying the company's "best in class" execution and "diverse" end markets position it well in a tougher cyclical environment. 4. Dominion (D) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying the company is entering a period of balance sheet improvement, de-risked business mix and overall simplification, with or without the Scana (SCG) assets. 5. Baker Hughes (BHGE) upgraded to Buy from Hold at Jefferies with analyst Brad Handler saying earnings power of $4 per share next decade "seems tangible," as is free cash flow conversion of greater than 90% of estimated earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ON ON Semiconductor
$16.79

0.28 (1.70%)

11/14/18
MSCO
11/14/18
NO CHANGE
MSCO
Underweight
Morgan Stanley says auto semiconductor estimates still too high
Morgan Stanley analyst Craig Hettenbach sees pressure building toward an eventual reset in the first half of 2019 for semiconductor companies that have so far characterized their automotive business as "stable." He believes estimates are still too high in autos and notes that his 2019 EPS estimate is 15% below the Street for ON Semiconductor (ON) and 5% below consensus for Sensata (ST). Having braced for a greater degree of negativity, Hettenbach was surprised that commentary on autos was mixed during earnings season, and he sees companies that have been slower to reset expectations being more susceptible to order reductions as suppliers and OEMs adjust to weaker than expected production, he tells investors. The analyst reiterates his Underweight ratings on both ON and Sensata.
11/13/18
BMOC
11/13/18
INITIATION
Target $20
BMOC
Market Perform
ON Semiconductor initiated with a Market Perform at BMO Capital
As reported earlier, BMO Capital analyst Ambrish Srivastava initiated ON Semiconductor with a Market Perform rating and a price target of $20. The analyst states that while he is impressed with the company's execution toward achieving its near-term and long-term target, he finds shares valued "reasonably" at current levels. Srivastava adds however that the "integration of the Fairchild acquisition has gone a long way to wipe away the sins of the Sanyo deal" and that he would consider taking a more constructive stance on downward estimate revisions or reduction of lead times.
11/12/18
BMOC
11/12/18
INITIATION
BMOC
Market Perform
ON Semiconductor initiated with a Market Perform at BMO Capital
BMO Capital analyst Ambrish Srivastava initiated ON Semiconductor with a Market Perform rating.
12/03/18
CHLM
12/03/18
NO CHANGE
CHLM
Auto suppliers should recover after U.S./China trade news, says Craig-Hallum
Craig-Hallum analyst Anthony Stoss expects auto supplier stocks to recover after positive meetings between President Trump and Chinese counterpart over the weekend. The analyst notes that 25% tariffs were pushed out 90 days to get final deal, and argues that automotive suppliers are too cheap and should work higher on the news. Stoss remains a buyer of STMicroelectronics (STM), ON Semiconductor (ON), and Cypress Semiconductor (CY) at current levels.
NXPI NXP Semiconductors
$75.02

1.82 (2.49%)

12/21/18
12/21/18
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) initiated with an Overweight at Piper Jaffray. 2. Biogen (BIIB) initiated with a Buy at BTIG. 3. Allena Pharmaceuticals (ALNA) assumed with a Buy at B. Riley FBR. 4. WWE (WWE) initiated with a Hold at Loop Capital. 5. Applied Materials (AMAT) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/18
PIPR
12/20/18
INITIATION
Target $100
PIPR
Overweight
NXP Semiconductors initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Harsh Kumar started NXP Semiconductors with an Overweight rating and $100 price target.
12/19/18
SUSQ
12/19/18
NO CHANGE
SUSQ
Neutral
Susquehanna sees Mellanox as top Semiconductors M&A target for 2019
Susquehanna analyst Christopher Rolland said he likes secular themes for the semiconductor group in 2019. He prefers themes like A.I. as well as industry M&A targets. The analyst noted handset unit growth is slowing heading into 2019 and there are automotive headwinds, tariffs, and risks to PC shipments, which are causing a shift in interest. Rolland said he considers Mellanox (MLNX) his top takeout candidate in the space, also identifying Lattice Semiconductor (LSCC), Cypress Semiconductor (CY) and ON Semiconductor (ON) "attractive" targets.
12/21/18
PIPR
12/21/18
INITIATION
Target $100
PIPR
Overweight
Piper sees attractive valuation for NXP, starts with Overweight raitng
Piper Jaffray analyst Harsh Kumar last night initiated coverage of NXP Semiconductors with an Overweight rating and $100 price target. The company is trading at an attractive valuation given its end-market exposure and solid financial position, Kumar writes in a note to investors. Despite near-term headwinds from trade and European emission testing, the automotive and industrial markets are the semiconductor end-markets to be in over the next several years, and roughly 70% of NXP's revenue comes from these end-markets, says the analyst. Further, Kumar believes NXP has one of the better cash flow generation models in the semiconductor business.
ADI Analog Devices
$85.90

0.06 (0.07%)

11/21/18
LOOP
11/21/18
NO CHANGE
Target $102
LOOP
Buy
Analog Devices price target lowered to $102 from $117 at Loop Capital
Loop Capital analyst Cody Acree lowered his price target on Analog Devices to $102 to reflect the broader industry multiple contraction, modelling an 18-times forward earnings multiple and a FY20 EPS of $5.54. The analyst also keeps his Buy rating after the company's Q4 earnings beat, saying the quarter was "not as bad as feared", adding that investors' positive reaction to the print "may signal an increased interest to move money back into semiconductors". Acree still maintains a somewhat cautious view based on Analog Devices' "commentary regarding tariff-related inflationary pressure, particularly in the industrial and automotive markets, which have been among the largest drivers of growth for the chip industry over the past few years."
11/21/18
RHCO
11/21/18
NO CHANGE
Target $106
RHCO
Buy
Analog Devices price target lowered to $106 from $118 at SunTrust
SunTrust analyst William Stein lowered his price target on Analog Devices to $106 to reflect the lower multiples of the broader semiconductors sector. The analyst keeps his Buy rating however and recommends that investors buy the stock ahead of "normalizing valuation" and potential for M&A benefits. Stein also believes that Analog Devices is navigating the trade tariff concerns "better than most peers owing to its strong position in comms and ongoing benefits from HITT and LLTC that are becoming more evident". The analyst anticipates the company outperforming in 2019 thanks to its lower than expected leverage and higher cost savings along with the industry's improving demand.
12/18/18
MSCO
12/18/18
DOWNGRADE
Target $100
MSCO
Equal Weight
Analog Devices downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach downgraded Analog Devices to Equal Weight from Overweight with a price target of $100. The analyst notes that while the company's guidance was "well ahead of peers", he sees it hard to remain positive on the stock considering the ongoing risks to semis in 2019. Hettenbach contends that Analog Devices should remain a "core long-term holding", but believes that its "elevated" estimates will make near term outperformance "difficult".
12/19/18
12/19/18
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alkermes (ALKS) downgraded to Sell from Neutral at Goldman Sachs with analyst Terence Flynn saying he removed sales of ALKS 5461 for depression from his model as well as the "M&A component" from his price target. He now sees 21% downside to his price target. 2. Analog Devices (ADI) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Craig Hettenbach saying while the company's guidance was "well ahead of peers", he sees it hard to remain positive on the stock considering the ongoing risks to semis in 2019. 3. Under Armour (UA, UAA) downgraded to Underweight from Neutral at Atlantic Equities. 4. Micron (MU) downgraded to Hold from Buy at Needham and to Sector Perform from Outperform at RBC Capital. 5. JPMorgan (JPM) downgraded to Neutral from Overweight at Atlantic Equities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CY Cypress Semiconductor
$12.85

0.14 (1.10%)

10/26/18
RHCO
10/26/18
NO CHANGE
Target $13.5
RHCO
Hold
Cypress Semiconductor price target lowered to $13.50 from $20 at SunTrust
SunTrust analyst William Stein lowered his price target on Cypress Semiconductor to $13.50 and kept his Hold rating, saying that while the company delivered a "solid" Q3, its Q4 guidance was below consensus on broad-based demand weakness - particularly in the consumer and industrial sectors in Asia. The analyst is positive on the company's SK Hynix NAND joint venture however, adding that he will look for a better entry point on bottoming fundamentals amid "depressed" valuation on the stock.
10/22/18
ROTH
10/22/18
NO CHANGE
Target $18
ROTH
Buy
Cypress Semiconductor price target lowered to $18 from $22 at Roth Capital
Roth Capital analyst Suji Desilva believes Cypress Semiconductor is on track for better than seasonal Q3 revenue growth and thinks its margin recovery progress remains intact. However, Desilva lowered his price target on Cypress to $18 from $22 to reflect broader semiconductor stock weakness. The analyst keeps a Buy rating on Cypress shares, stating that the recent pullback presents an attractive entry point.

TODAY'S FREE FLY STORIES

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

10:49
12/08/19
12/08
10:49
12/08/19
10:49
Hot Stocks
Fate Therapeutics announces vivo preclinical data for FT596 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

09:22
12/08/19
12/08
09:22
12/08/19
09:22
Hot Stocks
Agios says proof-of-concept has been established for mitapivat »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ZIOP

Ziopharm

$5.16

0.06 (1.18%)

09:20
12/08/19
12/08
09:20
12/08/19
09:20
Hot Stocks
Ziopharm reports pre-clinical data of Rapid Personalized Manufacture »

Ziopharm Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGTX

TG Therapeutics

$7.11

-0.57 (-7.42%)

09:18
12/08/19
12/08
09:18
12/08/19
09:18
Hot Stocks
TG Therapeutics reports triple therapy data from Phase I/II study of ublitux »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:16
12/08/19
12/08
09:16
12/08/19
09:16
Hot Stocks
Karyopharm says four posters will be presented at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPHA

Innate Pharma

$6.30

(0.00%)

09:13
12/08/19
12/08
09:13
12/08/19
09:13
Hot Stocks
Innate Pharma reports long-term data from Phase III trial of Lumoxiti »

Innate Pharma shared new,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.26

4.02 (1.09%)

09:11
12/08/19
12/08
09:11
12/08/19
09:11
Hot Stocks
Regeneron reports initial data for REGN5458 in myeloma patients »

Regeneron Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:09
12/08/19
12/08
09:09
12/08/19
09:09
Hot Stocks
Blueprint reports 77% overall response rate in 48 patients from Explorer trial »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:06
12/08/19
12/08
09:06
12/08/19
09:06
Hot Stocks
Blueprint announces initial data from Phase 2 Pioneer trial in mastocytosis »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.